Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Avogaro

Showing results (201-210 of 426) with videos related to

Pageof 43
Sort By:
Diabetologia|September 15, 2023
Improved prediction of long-term kidney outcomes in people with type 2 diabetes by levels of circulating haematopoietic stem/progenitor cellsBenedetta Maria Bonora, Mario Luca Morieri, Marella Marassi, et al.
The Journal of Clinical Endocrinology and Metabolism|October 5, 2023
Noninvasive Indices of MASLD Are Associated With Hypogonadism in Male Patients With Type 2 Diabetes MellitusNicola Caretta, Raffaele Scafa, Andrea Graziani, et al.
International Journal of Environmental Research and Public Health|November 26, 2022
Assessment of Glucose Lowering Medications' Effectiveness for Cardiovascular Clinical Risk Management of Real-World Patients with Type 2 Diabetes: Targeted Maximum Likelihood Estimation under Model Misspecification and Missing OutcomesVeronica Sciannameo, Gian Paolo Fadini, Daniele Bottigliengo, et al.
The Lancet Regional Health. Europe|February 8, 2024
Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal riskGian Paolo Fadini, Enrico Longato, Mario Luca Morieri, et al.
Diabetes Research and Clinical Practice|February 28, 2025
Exploring the benefits of alirocumab as lipid-lowering therapy in people with diabetes and very high cardiovascular riskAngelo Avogaro, Raffaella Buzzetti, Riccardo Candido, et al.
Diabetes Care|December 29, 2007
Maternal insulin therapy increases fetal endothelial progenitor cells during diabetic pregnancyGian Paolo Fadini, Ilenia Baesso, Carlo Agostini, et al.
Diabetes|March 2, 2002
Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetesRoldano Scognamiglio, Angelo Avogaro, Saula Vigili de Kreutzenberg, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 15, 2017
Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes MellitusMarc Evans, Plamen Kozlovski, Päivi M Paldánius, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 8, 2022
Glycaemic Control Achieves Sustained Increases of Circulating Endothelial Progenitor Cells in Patients Hospitalized for Decompensated Diabetes: An Observational StudyBenedetta Maria Bonora, Roberta Cappellari, Marco Grasso, et al.
Cardiovascular Diabetology|January 19, 2018
p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complicationsGian Paolo Fadini, Mattia Albiero, Benedetta Maria Bonora, et al.
Pageof 43

Showing results (201-210 of 426) with videos related to

Sort By:
Pageof 43
Diabetologia|September 15, 2023
Improved prediction of long-term kidney outcomes in people with type 2 diabetes by levels of circulating haematopoietic stem/progenitor cellsBenedetta Maria Bonora, Mario Luca Morieri, Marella Marassi, et al.
The Journal of Clinical Endocrinology and Metabolism|October 5, 2023
Noninvasive Indices of MASLD Are Associated With Hypogonadism in Male Patients With Type 2 Diabetes MellitusNicola Caretta, Raffaele Scafa, Andrea Graziani, et al.
International Journal of Environmental Research and Public Health|November 26, 2022
Assessment of Glucose Lowering Medications' Effectiveness for Cardiovascular Clinical Risk Management of Real-World Patients with Type 2 Diabetes: Targeted Maximum Likelihood Estimation under Model Misspecification and Missing OutcomesVeronica Sciannameo, Gian Paolo Fadini, Daniele Bottigliengo, et al.
The Lancet Regional Health. Europe|February 8, 2024
Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal riskGian Paolo Fadini, Enrico Longato, Mario Luca Morieri, et al.
Diabetes Research and Clinical Practice|February 28, 2025
Exploring the benefits of alirocumab as lipid-lowering therapy in people with diabetes and very high cardiovascular riskAngelo Avogaro, Raffaella Buzzetti, Riccardo Candido, et al.
Diabetes Care|December 29, 2007
Maternal insulin therapy increases fetal endothelial progenitor cells during diabetic pregnancyGian Paolo Fadini, Ilenia Baesso, Carlo Agostini, et al.
Diabetes|March 2, 2002
Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetesRoldano Scognamiglio, Angelo Avogaro, Saula Vigili de Kreutzenberg, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 15, 2017
Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes MellitusMarc Evans, Plamen Kozlovski, Päivi M Paldánius, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 8, 2022
Glycaemic Control Achieves Sustained Increases of Circulating Endothelial Progenitor Cells in Patients Hospitalized for Decompensated Diabetes: An Observational StudyBenedetta Maria Bonora, Roberta Cappellari, Marco Grasso, et al.
Cardiovascular Diabetology|January 19, 2018
p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complicationsGian Paolo Fadini, Mattia Albiero, Benedetta Maria Bonora, et al.
Pageof 43